TLR2 and neoplasm: The release of the nuclear DNA-binding molecule high-mobility group box 1 (HMGB1) by dying tumour cells activates TLR2 and TLR4 on DCs, resulting in an efficient processing and cross-presentation of tumour antigens and tumour regression20, 21.